{"prompt": "['List of Tables', 'Table 1', 'Annualized Bleed Rate with Emicizumab Prophylaxis Arm', 'versus No Prophylaxis Arm in Patients 12 Years of Age', '94', 'Table 2', 'Intra-Patient Comparison of Annualized Bleed Rate with', 'Emicizumab Prophylaxis versus Previous Bypassing Agent', 'Prophylaxis', '95', 'Table 3', 'Change in Haem-A-QoL Physical Health Score in Patients (>', '18 Years of Age) with No Prophylaxis versus Emicizumab', 'Prophylaxis at Week 25', '96', 'Table 4', 'Annualized Bleed Rate with Emicizumab Prophylaxis in', 'Pediatric Patients < 12 Years of Age (Interim Analysis)', '96', 'Table 5', 'Adverse Reactions Reported in 5% of Patients from Pooled', 'Clinical Trials with Emicizumab', '97', 'Table 6', 'Characterization of aPCC Treatment in Pooled Clinical Trials', '98', 'Table 7', 'Objectives and Corresponding Endpoints', '101', 'Table 8', 'Mean Change (%) in Annualized Bleeding Rates in', 'Patients Enrolled in ACE001JPIACE002JP', '104', 'Table 9', 'Central vs Local Laboratory Assessments', '117', 'Table 10', 'Guidelines for Management of Patients Who Experience', 'Specific Adverse Events', '128', 'Table 11', 'Coagulation Test Results Affected and Unaffected by', 'Emicizumab', '130', 'Table 12', 'Adverse Event Severity Grading Scale for Events Not', 'Specifically Listed in WHO Toxicity Grading Scale', '133', 'Table 13', 'Clopper-Pearson 95% Cls for the Incidence of AEs', '(Based on N=200)', '143', 'List of Figures', 'Figure 1', 'Study Design', '102', 'Emicizumab - F. Hoffmann-La Roche Ltd', '74 / Protocol MO39129, Version 3']['List of Appendices', 'APPENDIX 1', 'SCHEDULE OF ACTIVITIES', '156', 'APPENDIX 2', 'SCHEDULE OF BIOMARKER SAMPLES', '162', 'APPENDIX 3', 'EMIPREF PATIENT PREFERENCE', 'QUESTIONNAIRE', '164', 'APPENDIX 4', 'CLINICAL CRITERIA FOR DIAGNOSING', 'ANAPHYLAXIS', '166', 'APPENDIX 5', 'WHO TOXICITY GRADING SCALE FOR', 'DETERMINING THE SEVERITY OF LABORATORY', 'ABNORMALITIES AND ADVERSE EVENTS', '167', 'Emicizumab - F. Hoffmann-La Roche Ltd', '75 / Protocol MO39129, Version 3']['PROTOCOL AMENDMENT ACCEPTANCE FORM', 'TITLE:', 'A SINGLE-ARM, MULTICENTER PHASE IIIB', 'CLINICAL TRIAL TO EVALUATE THE SAFETY AND', 'TOLERABILITY OF PROPHYLACTIC EMICIZUMAB', 'IN HEMOPHILIA A PATIENTS WITH INHIBITORS', 'PROTOCOL NUMBER: MO39129', 'VERSION NUMBER:', '3', 'EUDRACT NUMBER:', '2016-004366-25', 'TEST PRODUCT:', 'Emicizumab (RO5534262)', 'MEDICAL MONITOR:', 'Dr.', 'MD, MBA', 'SPONSOR:', 'F. Hoffmann-La Roche Ltd', 'I agree to conduct the study in accordance with the current protocol.', \"Principal Investigator's Name (print)\", \"Principal Investigator's Signature\", 'Date', 'Please retain the signed original of this form for your study files. Please return a copy as', 'instructed by your local study monitor.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '76 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}